Equity
€1.5m from €4.0m in 2021
Equity fell by 64% in 4 years.
BIO.BE
Lifetime
17 annual accounts with figures on one time axis, 22 filings since 2004peak €3.0m (2019)
€506,347▲ 14.3%
lowest -€966,125 (2023)
-€244,508▲ €481,291
peak €4.0m (2021)
€1.5m▼ 14.9%
€1.6m▼ 20.5%
peak 28.1 FTE (2013)
5.4 FTE▼ 37.2%
Board30 names since 2006all names
5 directorsGauthier SAELENS and 4 others
Owners3 names in the annual accounts
consolidatesInstitut de Pathologie et de Génétique
Documentsfilings and deeds
19-06-202642 days before the deadline
2025financial year
Gross margin from €442,965 to €506,347Loss of €244,508Staff from 8.6 FTE to 5.4 FTE1 director appointed, 5 resignations, 2 reappointments 19-12Reappointment: RSM InterAudit (statutory auditor) 10-03Equity from €1.7m to €1.5m
Key points
from the 2025 annual accountsLosses
-€2.5m in four years
Every financial year from 2022 to 2025 closed with a loss. 2023 was the heaviest.
Staff
5.4 FTE from 28.1 in 2013
Between 2013 and 2025, 81% of the full-time equivalents disappeared.
Filings
22 annual accounts since 2004
The last five annual accounts were filed 23 to 42 days before the end of the period.
Board
2 joined
New directors. Latest change 21-11-2025 · 5 in office.
Position in the sector
-€244,508
Lower net result than 95% of companies in human health. Sector median €70,723 · 778 companies.
Checked score
89
Excellent
Financially stronger than 19% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,183 companies (NACE 86, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%lowest value
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.2%▲ +0.1 percentage points vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.2%● unchanged vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.3%▲ +0.1 percentage points vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026highest value
07-2026: 0.1%▼ -0.2 percentage points vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Loss of €244,508, the second in a row (financial year 2025)
lowers risk
Sector: Human health activities (NACE 86)
Figures for financial year 2025 (filed on 19-06-2026)
Equity €1.5m (47.9% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 38% of them on solvency, 9% on liquidity, 3% on profitability and 24% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 12,322 companies had the same profile as BIO.BE has now. Each dot stands for 31 companies, two years later.
90.3%
were still trading
8.6%
stopped another way
0.7%
went bankrupt
Another 0.5% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of BIO.BE itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 12,322 companies, not a prediction for BIO.BE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €120,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.9 (1.09 in 2024), below 1. Short-term debt is 37.5% and cash 5.2% of total assets. 52.1% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€244,508
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-06-2026, 42 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
42 days early
2024
28 days early
2023
23 days early
2022
35 days early
2021
39 days early
2020
24 days early
2019
31 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 32 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 26 June (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- Institut de Pathologie et de Génétique consolidatesannual accounts 2025
Recent changes
2 directors appointed, 1 statutory auditor reappointed
Reappointment: RSM InterAudit (statutory auditor) · Appointments: Coralie DANIEL and Tristan GEURTS · General meeting of 21-11-2025 · Gazette deed
1 director appointed, 5 resignations, 2 reappointments
Resignations: Pierre Coulie, Denis Dufrane, Michel Mahaux, Didier Thiebaut and François Fontaine · Reappointments: Jean-François Ghidetti and Gauthier Saelens · Appointment: Bernard Willemart · General meeting of 13-06-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0861738595
Reappointment: RSM InterAudit (statutory auditor)
General meeting of 28-06-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BIO.BE Charleroi | €3.0m | €506,347 | 47.9% | 5.4 |
| PRIMROSE LABORATORIES Torhout | €1.9m | €436,874 | -74.8% | 5.2 |
| DR. JANS RADIOLOOG Landen | €2.1m | €581,726 | 45.8% | 2.1 |
| RADIOLOGIE DOKTER FRANS Assenede | €2.2m | €607,290 | 88.2% | 2.2 |
| NV R.E.D. LABORATORIES Asse | €2.8m | €859,641 | 83.8% | 6.9 |
| MB DECLERCK Schoten | €1.9m | €463,084 | 76.9% | 2 |
| DOKTER BARBARA DE CLERCQ Koksijde | €1.8m | €442,676 | 36.8% | 1.9 |
These companies have the same main activity as BIO.BE: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €1.8m and €2.8m, founded between 1998 and 2007.
Official details
Source: KBO- Status
- Active since 20-11-2003Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910and 2 others
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment units
- 2.214.938.2836041 Charleroi, since 20-11-2003
- 2.234.696.6886041 Charleroi, since 20-11-2003
- Financial year end
- 31 December
- Peppol
- Reachable since 17-10-2025
Annual accounts 2025
- ≈ €880,000estimated
- €3.0m▼ 17.9%
- Employeeson 31-12-2025
- 5▼ 37.5%
- Filing
- Filed on 19-06-2026, 42 days before the end of the filing period
Insights on BIO.BE
BIO.BE has existed since 2003. The gross margin fell from €2.3m in 2021 to €234,100 in 2023 and staff from 23.3 to 10.3 full-time equivalents.
In June 2025, five directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BIO.BE
- What is the company number of BIO.BE?
- The company number of BIO.BE is 0861.738.595. The VAT number is the same number with BE in front: BE 0861.738.595.
- Where is BIO.BE based?
- The registered office is at Avenue Georges Lemaitre 25, 6041 Charleroi.Company details
- What does BIO.BE do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of BIO.BE?
- BIO.BE is a public limited company (NV).
- When was BIO.BE founded?
- BIO.BE was founded on 20-11-2003.
- Is BIO.BE still active?
- Yes, BIO.BE is an active enterprise in the KBO register.
- How many employees does BIO.BE have?
- BIO.BE had an average of 5.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does BIO.BE fall under?
- In its 2025 annual accounts, BIO.BE states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of BIO.BE?
- The turnover in financial year 2025 is ≈ €880,000. This figure is estimated from the gross margin of €506,347 and 55 comparable companies (NACE 86). It probably lies between €640,000 and €1.5m.
- Is BIO.BE profitable?
- In financial year 2025, BIO.BE made a loss of €244,508.
- Where can I find the annual accounts of BIO.BE?
- BIO.BE filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BIO.BE due?
- BIO.BE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.